Alexion bags Ultomiris EU approval for paroxysmal nocturnal hemoglobinuria

pharmanewsdaily- July 5, 2019 0

Ultomiris EU approval : Alexion Pharmaceuticals has secured approval from the European Commission (EC) for its C5 complement inhibitor Ultomiris (ravulizumab) for the treatment of ... Read More